MGNX MacroGenics Inc.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in August: 

  • BTIG Virtual Biotechnology Conference. MacroGenics’ management will participate in one-on-one meetings and a fire-side chat discussion hosted by the analyst on Monday, August 10, 2020 at 12:30 p.m. ET.
  • Wedbush PacGrow Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on August 12, 2020, at 8:35 a.m. ET.

Webcasts of each presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at /events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

CONTACT:
Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172,
EN
05/08/2020

Underlying

MGNXMacroGenics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Reports Second Quarter 2025 Financial Results and Highligh...

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing inn...

3h / 27m 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Appoints Eric Risser as President and Chief Executive Offi...

MacroGenics Appoints Eric Risser as President and Chief Executive Officer ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company’s corporate development...

August 13, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty P...

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard i...

June 10, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthc...

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under ...

June 3, 2025 1 EN
 PRESS RELEASE
Free
MGNX MacroGenics In...

MacroGenics Provides Update on Corporate Progress and First Quarter 20...

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch